Screening for Hereditary Transthyretin Amyloidosis in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (hATTR IN CIDP)
Summary
The purpose of this research study is to determine if some people diagnosed with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) may have another genetic disease that can cause nerve damage, called hereditary TTR amyloidosis (hATTR). hATTR is treated very differently than CIDP, so understanding if hATTR is sometimes incorrectly diagnosed as CIDP is important.
Eligibility
Eligible gender: Male, Female, Transgender, Other
Eligible ages: 18 to 120
Inclusion criteria:
You are eligible for this study if you are:
1. Age 18-years or older.
2. Have a clinical diagnosis of CIDP by a neuromuscular specialist.
3. Are seeing for your disease in the University of Calgary Neuromuscular Clinic.
Exclusion criteria:
You are not eligible for this study if you are:
1. Unable to understand the informed consent process due to cognitive or language barriers.
Participate
Fill out the following form if you want to participate in this research
Collection of personal information
Your personal information is collected under
the authority of section 33(c) of the Freedom of Information and Protection of Privacy Act. If
you have any questions about the collection or use of this information, please visit our
Access to Information page.
Additional information
Contact information
Dr. Gordon Jewett nmresearch@ucalgary.ca
Principal investigator:
Gordon Jewett
Clinical trial:
No
REB-ID:
REB23-0437